注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

【转载】The Lancet-Oncology(Jul 25,2016)  

2016-07-26 13:37:23|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Logo
Weekly Update
Jul 25, 2016
Weekly Features:
Clinical Pictures
NEW | Clinical Picture - Call for submissions
The Lancet Oncology is issuing a call for Clinical Pictures which should provide visual information that will be useful to other clinicians. Pictures should be interesting, educational, and respectful of the patient.
Learn more →
Frontiers of Oncology
Meeting | UCL Frontiers of Oncology: Women's Health
Now booking - the UCL Frontiers of Oncology: Woman’s Health conference, London September 28th. Free to Lancet Oncology readers.
Find out more →
Online First:
NEWS
IVF treatment not linked to breast cancer
The use of in-vitro fertilisation (IVF) does not increase the risk of breast cancer, according to the findings of a long-term cohort study.
Read this Report →
Steve Gschmeissner/Science Photo Library
NEWS
Resistance to PD-1 blockade in melanoma
A new study by Antoni Ribas and colleagues has identified two likely mechanisms for the development of resistance to PD-1 blockade in patients with melanoma.
Read this Report →
Life In View/Science Photo Library
NEWS
Ipilimumab for relapse after allogeneic transplantation
Induction therapy with ipilimumab might produce durable responses for patients with relapse of haematological cancers after allogeneic haemaopoietic stem-cell transplantation, a phase 1/1b multicentre study from the USA suggests.
Read this Report →
John Mead/Science Photo Library
NEWS
9th International Conference on Head and Neck Cancer
News in Brief from the 9th International Conference on Head and Neck Cancer, which was held on July 16–20, 2016, in Seattle, WA, USA.
Read this Report →
CNRI/Science Photo Library
COMMENT
Is nivolumab an option for Hodgkin's lymphoma?
Christian Gisselbrecht comments on Anas Younes and colleagues' report on the results of a phase 2 study to assess the activity of nivolumab in 80 adult patients with classical Hodgkin's lymphoma who had failed to respond to both autologous stem-cell transplantation (ASCT) and brentuximab vedotin.
Read this Comment →
ARTICLES
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
This study aimed to assess the clinical benefit and safety of nivolumab monotherapy in patients with classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin.
Read this Article →
Steve Gschmeissner/Science Photo Library
COMMENT
Mutated BRAF and personalised medicine in differentiated thyroid cancer
Keith Bible and Mabel Ryder comment on the findings of a phase 2 study of vemurafenib that reflects the emerging era of personalised medicine in differentiated thyroid cancer.
Read this Comment →
ARTICLES
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
This study aimed to establish the activity of vemurafenib in patients with BRAFV600E-positive papillary thyroid cancer.
Read this Article →
Announcements:
Stay Connected
Stay Connected
If you would prefer not to receive these weekly updates, but wish to continue receiving the monthly Table of Contents alert, please click here:
Unsubscribe from Weekly Updates →

Follow us on Twitter
For all the very latest news, comment, and research follow The Lancet Oncology on Twitter.
Follow us →
The Lancet Choice
Access 5 articles from The Lancet Clinic for just $49.00
The Lancet Choice is a new payment option that gives you the freedom to access 5 premium articles of your choice from The Lancet Clinic's ever-growing collection of disease pages - all for the reduced introductory rate of $49.00.
Find out more →
This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. 

Copyright ? 2016 Elsevier Limited. All rights reserved. THE LANCET ? is a registered trademark of RELX Intellectual Properties SA, used under license. 

To unsubscribe from The Lancet Oncology Weekly Updates, but continue receiving the monthly Table of Contents alert, please click here →

To unsubscribe from all Table of Contents alerts, please edit your mailing preferences by logging in to your TheLancet.com account: 

Update mailing preferences
The Lancet-Oncology(Jul 25,2016) - liusongjifan2 - liusongjifan2的博客 The Lancet-Oncology(Jul 25,2016) - liusongjifan2 - liusongjifan2的博客
  评论这张
 
阅读(2)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017